Compound Details
SPIROCLEN tablets contain Clenbuterol Hydrochloride (CAS 21898-19-1). Pharmaceutical-grade compound by NovaTech Sciences supporting metabolic activity, endurance, and performance environments.
Form
Oral tablet
Strength
40 mcg Clenbuterol Hydrochloride per tablet
Pack Size
10 tablets per pack
Packaging
Compact, secure, and pharmaceutical-grade
Usage
Cutting cycles, fat-loss, metabolic enhancement, and muscle preservation
Storage
Store in a cool, dry place away from sunlight.
SPIROCLEN Tablets by NovaTech Sciences contain pharmaceutical-grade Clenbuterol Hydrochloride (CAS 21898-19-1), a beta-2 adrenergic receptor agonist recognized for its association with metabolic stimulation, endurance environments, and respiratory support pathways. Clenbuterol Hydrochloride is globally identified through CAS 21898-19-1, ensuring chemical authenticity, compound traceability, and pharmaceutical-grade standardization across international markets.
NovaTech Sciences manufactures Clenbuterol Hydrochloride CAS 21898-19-1 under strict pharmaceutical quality protocols designed to maintain compound purity, dosage precision, and consistent global supply.
Clenbuterol Hydrochloride, registered under CAS 21898-19-1, is a long-acting beta-2 adrenergic receptor agonist. It has been studied in pharmaceutical contexts related to bronchodilation and metabolic stimulation.
The CAS registry number 21898-19-1 serves as the internationally recognized chemical identifier for Clenbuterol Hydrochloride. This identifier ensures compound verification, regulatory transparency, and consistent identification across pharmaceutical manufacturing and global distribution networks.
Clenbuterol has been associated with metabolic activation processes and respiratory system stimulation through its interaction with beta-adrenergic receptors.
Clenbuterol Hydrochloride (CAS 21898-19-1) works by stimulating beta-2 adrenergic receptors located in smooth muscle tissue and metabolic pathways throughout the body.
Through these mechanisms, Clenbuterol CAS 21898-19-1 is associated with metabolic signaling pathways that influence energy expenditure and respiratory function.
Each batch of Clenbuterol CAS 21898-19-1 undergoes extensive laboratory testing to confirm compound identity, purity verification, and dosage consistency.
NovaTech Sciences operates as a trusted manufacturer, supplier, and exporter of pharmaceutical-grade metabolic and performance compounds for international markets. By specifying CAS 21898-19-1, SPIROCLEN tablets maintain chemical authenticity and regulatory transparency.
These processes ensure Clenbuterol Hydrochloride tablets meet strict pharmaceutical distribution standards.
NovaTech Sciences emphasizes pharmaceutical precision, regulatory compliance, and compound reliability. SPIROCLEN tablets containing Clenbuterol Hydrochloride CAS 21898-19-1 are produced using advanced pharmaceutical technologies designed to maintain consistent compound quality.
For pharmaceutical distributors and professional markets seeking a dependable source of Clenbuterol Hydrochloride (CAS 21898-19-1), SPIROCLEN Tablets by NovaTech Sciences provide verified compound identity, pharmaceutical manufacturing excellence, and reliable global supply. Supported by strict quality assurance protocols, Clenbuterol CAS 21898-19-1 remains a recognized beta-2 adrenergic compound associated with metabolic stimulation, endurance environments, and respiratory support pathways.
Precautions
Contraindications
Clenbuterol Hydrochloride is the hydrochloride salt of clenbuterol, identified by CAS Number 21898-19-1. It has the molecular formula C12H19Cl3N2O and a molecular weight of approximately 313.65 g/mol. The compound belongs to the beta-adrenergic agonist category and has bronchodilator activity through its interaction with beta-2 adrenergic receptors.
Nova Techsciences associates Clenbuterol Hydrochloride with its SPIROCLEN oral tablet range. The current compound page lists the active ingredient, CAS number and tablet presentation. Website information should remain consistent with the finished packaging, batch records, structured data and Certificate of Analysis.
Clenbuterol Hydrochloride should be distinguished from clenbuterol base, which has a different CAS identifier. Using the correct salt name and chemical number helps prevent inconsistencies across labels, laboratory reports and technical documentation.
Clenbuterol stimulates beta-2 adrenergic receptors in smooth muscle. This explains its historical investigation and authorised use as a bronchodilator in certain countries. However, its regulatory status is not uniform across Europe. EMA records show that clenbuterol-containing human medicines have held national authorisations in only certain EU member states, so therapeutic claims must be checked against the current authorisation in each intended market.
For the United Kingdom, Netherlands and other European markets, Nova Techsciences should clearly disclose the compound’s marketing-authorisation status, legal supply category, responsible organisation and adverse-event reporting process.
A reliable Clenbuterol Hydrochloride compound profile should be supported by documented analytical controls. Appropriate records may include raw-material identification, active-compound assay, impurity analysis, reference-standard comparison, tablet content uniformity, dissolution testing, stability assessment and packaging-integrity verification.
Every manufactured batch should carry a unique number linked to its production history and laboratory-release results. Claims concerning pharmaceutical quality, purity or manufacturing standards should only be published when supported by current, verifiable documentation.
Clenbuterol can affect the cardiovascular and nervous systems. Reported concerns include palpitations, increased heart rate, tremor and nervousness. People with cardiovascular disease, abnormal heart rhythm, hypertension or hyperthyroidism may face additional risks.
Clenbuterol Hydrochloride should not be presented for weight loss, physique enhancement, athletic performance or unsupervised use. It is classified as a prohibited anabolic agent under the 2026 World Anti-Doping Agency Prohibited List and is prohibited both in and out of competition.
Stanozolol USP is an anabolic-androgenic steroid identified by CAS Number 10418-03-8. Nova Techsciences associates it with the lower-strength STANOVA tablet presentation. Its documentation should independently address liver, cardiovascular, hormonal and reproductive risks.
STANOVA-50 contains the same Stanozolol active compound but in a different product strength. It retains CAS Number 10418-03-8, while its packaging, strength, batch details and safety warnings should be clearly distinguished from the lower-strength presentation.
Clomiphene Citrate is a selective oestrogen receptor modulator identified by CAS Number 50-41-9. It is associated with medically supervised treatment of ovulatory dysfunction and requires separate contraindication, pregnancy, visual-effect and ovarian-response information.
Testosterone Propionate is an esterified testosterone compound identified by CAS Number 57-85-2. It is chemically and pharmacologically different from Clenbuterol Hydrochloride and requires independent information covering authorised status, contraindications, sterility controls and hormonal monitoring.
A Testosterone Blend combines more than one testosterone component. The individual esters and strengths should be identified separately rather than relying only on CAS Number 58-22-0, which identifies the parent testosterone compound.
Clenbuterol Hydrochloride should ultimately be presented through accurate chemical identification, transparent batch documentation, balanced safety information and clearly verified regulatory status.
Premium aromatase inhibitor tablets for estrogen suppression and effective hormone balance support.
Buy Tamoxifen Citrate (CAS 54965-24-1) by NovaTech Sciences. Premium tablets for estrogen modulation, hormone support, and targeted receptor activity.
Buy Anastrozole (CAS 120511-73-1) by NovaTech Sciences. Pharmaceutical-grade aromatase inhibitor tablets for estrogen suppression and hormone regulation.
